Vorapaxar for Secondary Prevention of Thrombotic Events for Patients With Previous Myocardial Infarction: A Prespecified Subgroup Analysis of the TRA 2°P-TIMI 50 Trial

Study Questions:

What is the effect of adding other antiplatelet drugs to aspirin for long-term secondary prevention of thrombotic events in stable patients with previous myocardial infarction (MI)?